NeoSickle makes a successful transition to the new IVD regulations
Biomaneo's first IVDR CE-certified product
Detection of a new case of Hb Wanjiang.
This discovery was the subject of a new publication
Biomaneo becomes a subsidiary of Shimadzu Corporation
Biomaneo becomes a wholly-owned subsidiary of Shimadzu Corporation (Kyoto, Japan)
4th Global Congress on Sickle Cell Disease
Join Biomaneo & Shimadzu at the 4th Global Congress on Sickle Cell Disease taking place in Paris from June 16-18.
Biomaneo obtains ISO 13485:2016 certification and strengthens its quality team
A key step for the marketing of its In Vitro Diagnostic Devices (IVDD) and in the transition to the new 2017/746 regulation.